Cellectis S.A. (0WA2)
LSE
Real-time Data
07:00 AM
Day's Range
2.7652 wk Range
2.07Overview - 0WA2 - Cellectis S.A.
Key Statistics
Valuation
Enterprise Value
56.70M
P/E (Trailing)
‪-4.25‬
Price / Sales (TTM)
‪8.42‬
Price / Book
‪1.66‬
EV / EBITDA
‪-0.93‬
Profitability
Gross Margin
‪54.96%‬
Profit Margin
‪86.57%‬
Operating Margin
‪-319.79%‬
Return on Assets
‪-18.04%‬
Return on Equity
‪-62.86%‬
Ownership
Shares Outstanding
100.69M
Float
39.37M
Held by Insiders
‪0.00%‬
Held by Institutions
‪20.93%‬
Price stats
Beta
‪2.08‬
50-Day Avg
‪2.58‬
200-Day Avg
‪3.24‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 0WA2 - Cellectis S.A.
Peers - 0WA2 - Cellectis S.A.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0WA2LSECellectis S.A.210.25MMarket Cap+18.23%52-week change-4.31P/E (Trailing)‪86.57%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0WA2 - Cellectis S.A.
About
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf"…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
